医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MabPlex Announces Expansion of cGMP Manufacturing Facilities

2016年10月04日 PM08:00
このエントリーをはてなブックマークに追加


 

FREMONT, Calif. & YANTAI, China

MabPlex International Ltd. (MabPlex), a global CRO/CMO service provider specializing in the development and manufacturing of antibody therapeutics and antibody-drug conjugates (ADC), today announced that it has broken ground on the expansion of its biomanufacturing facilities in China. The current 275,000 sq. ft. facility will soon be running at full capacity. In order to effectively serve customers better MabPlex is expanding their current CDMO facility. The new 428,000 sq. ft. facility is expected to be completed by August of 2017. The Utility and HVAC validation should be finished by December 2017 and the fill/finish facility will be completely validated by March of 2018. “With this expansion we believe that we will be able to meet our customers’ needs in biologics for the foreseeable future,” says Qibin Liang, President of MabPlex.

The current 275,000 sq. ft. facility will be entirely converted to ADC manufacturing and development space while the new 428,000 sq. ft. facility will be for mAb and other biologic manufacturing. This expansion will allow for six complete 2,000L bioreactor suites or 6 independent manufacturing lines (6x25L, 6x200L, 6x500L and 12×2,000L single use bioreactors). Six purification suites, a 37,000sq ft. cGMP Warehouse, and fill finish lines with capabilities up to 10,000 vials/hr. for mAb and 12,000 vials/hr. for ADC will be housed in these new buildings.

About MabPlex

MabPlex, founded in 2013, specializes in providing one-stop biologics development and manufacturing solutions to customers globally with our services from cell line development and process development to GMP manufacturing. Our technical expertise allows us to provide effective and high-quality solutions for monoclonal antibody and ADC therapeutics to the biopharmaceutical industry. With this, MabPlex delivers our commitment to our partners through our quality manufacturing, meeting their expectations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005500/en/

CONTACT

MabPlex USA, Inc.
Bethanne Deuel, MBA, 1-800-925-3608
Director
of Marketing and Communications
bdeuel@us.mabplex.com
www.mabplex.com

同じカテゴリーの記事 

  • Pacific Islands Primary Care Association and HealthEfficient Partners with eClinicalWorks to Expand Community Access to Comprehensive Health Center Solutions
  • Ora and Singapore Eye Research Institute Unveil Groundbreaking Partnership to Propel Ophthalmology Innovation Globally
  • ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
  • Shaperon to Conduct Strategic Partnering and Institutional Investor Meetings at the 10th Annual BFC Healthcare Business Development & Investment Conference in Shanghai
  • Makana™ Issued Patent in South Korea for Its Genetically-Modified TKO Pig for Use in Xenotransplantation